Aspartate Aminotransferase (AST): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Aspartate aminotransferase is an enzyme found predominantly in the heart, liver, skeletal muscle, kidneys, brain, pancreas, and red blood cells. It catalyses the reversible transfer of an amino group between aspartate and alpha‑ketoglutarate, a critical reaction in amino acid metabolism and the malate‑aspartate shuttle. When cells containing AST are damaged, the enzyme leaks into the bloodstream, making it a sensitive – though entirely non‑specific – marker of cellular injury.

AST is routinely measured alongside alanine aminotransferase (ALT) as part of the liver panel. The pattern and degree of elevation, particularly the AST:ALT ratio, provides valuable diagnostic clues:

· Hepatocellular injury – viral hepatitis, drug‑induced liver injury, ischaemia

· Alcohol‑related liver disease – AST typically > ALT, often with ratio ≥2:1

· Cirrhosis – ratio may reverse as ALT declines

· Extrahepatic sources – haemolysis, muscle injury, myocardial infarction, thyroid disease

Unlike ALT, which is more specific to the liver, AST is a generalist – its elevation demands consideration of cardiac, muscular, haematologic, and renal causes alongside hepatic pathology.

---

2. What does it measure

a. Units of measurement

· Units per litre (U/L) – conventional and SI units

· Microkatal per litre (µkat/L) – 1 U/L = 0.0167 µkat/L

b. Normal range

Reference intervals vary by laboratory, age, sex, and assay method. The following are typical adult ranges.

Population Typical reference range (U/L)

Adult males 10 – 40 U/L

Adult females 9 – 32 U/L (slightly lower due to lower muscle mass)

Children 15 – 50 U/L (higher in infancy, decline through adolescence)

Infants Up to 60 U/L

Older adults (>65 years) May be slightly higher; no consensus

Critical values:

· >500 U/L – suggests massive hepatocellular injury (viral, ischaemic, toxin)

· >1000 U/L – seen in ischaemic hepatitis (shock liver), acetaminophen toxicity, acute viral hepatitis, autoimmune hepatitis flare

Note: AST is not part of the standard cardiac enzyme panel in contemporary practice (troponin is superior). Historical use for myocardial infarction (AST rises 6–12 hours, peaks 24–48 hours) is now obsolete.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise AST)

Hepatic causes:

· Viral hepatitis – A, B, C, D, E; acute infection: AST often 500–3000 U/L; chronic: mild elevation (50–200 U/L)

· Alcohol‑related liver disease – AST > ALT, ratio ≥2:1; AST rarely >300 U/L in uncomplicated alcoholic hepatitis; higher if superimposed ischaemia or acetaminophen

· Non‑alcoholic fatty liver disease (NAFLD) – mild elevation (AST, ALT 30–100 U/L); ALT usually ≥ AST

· Drug‑induced liver injury – acetaminophen (massive elevation), isoniazid, nitrofurantoin, valproate, statins (rare), amiodarone, methotrexate

· Autoimmune hepatitis – variable; may be >1000 U/L during flares

· Cirrhosis – mild elevation; AST may exceed ALT as disease progresses

· Ischaemic hepatitis (shock liver) – sudden, massive elevation (1000–10,000 U/L); rapid decline with haemodynamic stabilisation

· Bile duct obstruction – mild to moderate elevation (typically <300 U/L); ALT often higher early; AST may rise later with secondary hepatocellular injury

· Hepatocellular carcinoma – variable; may be normal or mildly elevated

· Wilson disease – AST may exceed ALT; low alkaline phosphatase, low uric acid

Extrahepatic causes:

· Cardiac – myocardial infarction (historical), myocarditis, heart failure with hepatic congestion

· Muscular – rhabdomyolysis (CK > AST), strenuous exercise, seizures, trauma, polymyositis, muscular dystrophy, statin myopathy

· Haematologic – haemolysis (AST released from red blood cells; LDH also elevated), megaloblastic anaemia (ineffective erythropoiesis)

· Renal – acute kidney injury, renal infarction

· Pancreatic – acute pancreatitis

· Thyroid – hypothyroidism (reversible elevation)

· Pulmonary – pulmonary embolism (rare)

Medications:

· Raise AST: Statins (1–3% incidence, dose‑dependent), acetaminophen (toxic dose), NSAIDs, certain antibiotics, anticonvulsants, antiretrovirals, azole antifungals, methotrexate, amiodarone

· Lower AST: Metformin, vitamin D, silymarin (weak evidence)

b. Indirect correlation (factors influencing interpretation)

· Sex – females have lower baseline AST due to lower muscle mass

· Age – children have higher baseline; elderly may have slightly higher values

· Body mass index – obesity associated with higher AST (NAFLD)

· Muscle mass – individuals with high muscle mass have higher baseline AST

· Exercise – strenuous exercise causes transient elevation (24–72 hours) from muscle membrane permeability

· Race/ethnicity – African American individuals may have slightly higher AST

· Alcohol consumption – chronic use induces mitochondrial AST (mAST), contributing to elevated serum AST and high AST:ALT ratio

· Haemolysis – in vitro lysis of red blood cells releases AST; major cause of spurious elevation

· Sample storage – AST is stable for 3–5 days at 4°C; prolonged storage at room temperature causes gradual decline

· Circadian variation – slight; lowest in afternoon

· Pregnancy – mild elevation possible; hyperemesis gravidarum may cause moderate elevation

· Caffeine – acute ingestion may transiently lower AST? (conflicting data)

---

4. Disorders related to abnormal values

a. When markedly elevated (>500 U/L)

Hepatocellular necrosis pattern – indicates significant acute liver injury:

· Acute viral hepatitis – A, B (including reactivation), E; also EBV, CMV, herpes simplex (immunocompromised)

· Ischaemic hepatitis (shock liver) – hypotensive episode, sepsis, cardiac arrest; AST rises rapidly (often >3000 U/L), falls within 24–72 hours with haemodynamic recovery; ALT also elevated, LDH often >1000 U/L

· Drug‑induced liver injury – acetaminophen toxicity (single dose >7.5–10 g; AST often >3000 U/L, peaks at 72–96 hours), Amanita phalloides mushroom poisoning, cocaine, ecstasy

· Autoimmune hepatitis – acute presentation; often with elevated IgG, positive autoantibodies

· Acute bile duct obstruction – occasional, particularly with ascending cholangitis; usually <500 U/L but can be higher

· Wilson disease – acute liver failure presentation; AST > ALT, alkaline phosphatase low

Distinguishing feature: AST > 1000 U/L narrows the differential to ischaemia, toxin, acute viral hepatitis, autoimmune hepatitis, or Wilson disease. Alcoholic hepatitis rarely exceeds 300 U/L.

b. When moderately elevated (100 – 500 U/L)

· Chronic viral hepatitis (B, C) – fluctuating

· Alcoholic hepatitis – AST > ALT, ratio ≥2:1, AST typically <300 U/L

· Non‑alcoholic steatohepatitis (NASH) – AST and ALT usually <250 U/L

· Drug‑induced liver injury (mild to moderate)

· Autoimmune hepatitis (chronic or mild flare)

· Cirrhosis – any cause; AST often exceeds ALT in advanced disease

· Bile duct obstruction – choledocholithiasis, stricture, malignancy

· Metastatic liver disease – variable

· Muscle injury – rhabdomyolysis (CK >10,000 U/L; AST:ALT ratio >3:1)

· Haemolysis – mild elevation (LDH disproportionately high)

c. When mildly elevated (<100 U/L)

· Non‑alcoholic fatty liver disease (NAFLD) – most common cause in developed world

· Chronic hepatitis C – often normal or near‑normal

· Haemochromatosis – normal or mild elevation

· Alpha‑1 antitrypsin deficiency

· Coeliac disease – up to 40% have mild transaminase elevation; resolves with gluten withdrawal

· Thyroid disease – hypothyroidism

· Strenuous exercise – transient

· Gilbert syndrome – does not cause AST elevation; incidental finding

· Macro‑AST – benign phenomenon; AST bound to immunoglobulin, prolonged half‑life; normal ALT, normal workup; confirm by polyethylene glycol precipitation

d. When low

· Chronic kidney disease – dialysis patients often have low AST (pyridoxine deficiency); ALT also low

· Vitamin B6 (pyridoxine) deficiency – AST and ALT require pyridoxal‑5′‑phosphate as cofactor; levels may be falsely low

· Uraemia – inhibits enzyme activity in vitro

· Pregnancy – mild physiological decline in third trimester

---

5. Best way to address aberrant levels

Critical principle: AST is a marker of cellular injury, not a toxin. Treating the number without identifying the cause can delay diagnosis of treatable liver disease, muscle disorders, or drug toxicity. All interventions must be directed at the underlying condition.

a. Quick ways or using Medications

Cause‑specific therapy – examples:

· Viral hepatitis:

· Acute A/B/E: supportive care; no antiviral indicated unless fulminant

· Chronic hepatitis B: tenofovir, entecavir

· Chronic hepatitis C: direct‑acting antivirals (DAAs) – cure rate >95%

· Alcoholic hepatitis:

· Abstinence – essential

· Severe (Maddrey discriminant function ≥32): prednisolone 40 mg/day x 28 days, or pentoxifylline (second‑line)

· Nutritional support

· Drug‑induced liver injury:

· Discontinue offending agent

· Acetaminophen toxicity: N‑acetylcysteine (NAC) – most effective within 8–12 hours, beneficial up to 72 hours

· NAC also used for non‑acetaminophen acute liver failure (improves transplant‑free survival)

· Ischaemic hepatitis:

· Treat underlying cause (hypotension, sepsis, heart failure)

· AST normalises within 3–7 days of haemodynamic stabilisation

· Autoimmune hepatitis:

· Prednisolone ± azathioprine

· Response in 2–4 weeks; aim for normalisation of AST/ALT

· NAFLD/NASH:

· Weight loss (≥7% improves steatosis, inflammation, and fibrosis)

· Vitamin E 800 IU/day (non‑diabetic, biopsy‑proven NASH) – reduces AST/ALT and steatosis

· Pioglitazone (diabetic or insulin‑resistant NASH)

· Statins – safe in NAFLD; do not cause significant transaminase elevation in most patients

· Bile duct obstruction:

· ERCP with sphincterotomy/stenting

· AST normalises rapidly after relief of obstruction

· Haemochromatosis:

· Phlebotomy; AST normalises with iron depletion

· Wilson disease:

· Chelation therapy (D‑penicillamine, trientine), zinc

· Coeliac disease:

· Gluten‑free diet; AST normalises within 6–12 months

· Hypothyroidism:

· Levothyroxine; AST normalises with euthyroid state

Medications that lower AST (specific contexts):

· N‑acetylcysteine – acetaminophen toxicity, non‑acetaminophen acute liver failure

· Corticosteroids – autoimmune hepatitis, alcoholic hepatitis

· Ursodeoxycholic acid (UDCA) – primary biliary cholangitis (improves enzymes, not primarily AST)

· Vitamin E – NASH

· Pioglitazone – NASH

Do not use silymarin, glycyrrhizin, or herbal hepatoprotectives in place of definitive therapy.

b. Using Supplements or Holistic medicine

Supportive, adjunctive – never primary therapy for pathological AST elevation.

For liver health (hepatocellular injury):

· N‑acetylcysteine (NAC): Beyond acetaminophen toxicity, NAC has been studied in non‑acetaminophen acute liver failure, alcoholic hepatitis, and chronic hepatitis C. Meta‑analyses show mixed results; may improve transplant‑free survival in acute liver failure but does not clearly reduce mortality. Reasonable adjunct in severe acute hepatitis under medical supervision.

· Form: Oral (600–1200 mg/day) or intravenous (hospital setting).

· Source: Synthetic; acceptable.

· Milk thistle (Silybum marianum): Silymarin has antioxidant, anti‑inflammatory, and antifibrotic properties in vitro and animal models. Human trials are heterogeneous and of variable quality. Modest reductions in AST/ALT reported in alcoholic liver disease and viral hepatitis, but no consistent improvement in histology or mortality.

· Form: Standardised to 70–80% silymarin; dose 140–420 mg/day.

· Note: Does not replace antiviral therapy, corticosteroids, or abstinence.

· Caution: Weak phytoestrogen; avoid in oestrogen‑sensitive cancers.

· Curcumin: Anti‑inflammatory, antioxidant; reduces oxidative stress in liver disease. Small trials show modest AST reduction in NAFLD.

· Must use bioavailable formulation: Phytosome, liposomal, nanoparticle, or with piperine. Plain curcumin is ineffective systemically.

· Dose: 500–1500 mg/day of bioavailable curcuminoids.

· Source: Turmeric (Curcuma longa) rhizome extract, standardised to ≥95% curcuminoids.

· Caution: May interfere with certain chemotherapy agents; consult oncologist.

· Vitamin E: For non‑diabetic NASH with biopsy‑proven disease. PIVENS trial showed improvement in steatosis, inflammation, and ballooning with 800 IU/day. Does not improve fibrosis.

· Form: Mixed tocopherols or RRR‑alpha‑tocopherol (natural form). Avoid synthetic dl‑alpha‑tocopherol.

· Caution: High‑dose vitamin E (>400 IU/day) associated with increased all‑cause mortality and haemorrhagic stroke in meta‑analyses; use only under hepatologist guidance for confirmed NASH.

· Vitamin D3: Deficiency is common in chronic liver disease and correlates with disease severity. Supplementation improves bone health and may reduce fibrosis progression.

· Source: Lichen‑derived cholecalciferol (D3), not D2.

· Recheck serum 25‑hydroxyvitamin D after 3 months.

· Zinc: Deficiency common in cirrhosis (especially alcohol‑related). Supplementation (50 mg elemental zinc/day) improves hepatic encephalopathy and may reduce infection risk. No direct effect on AST.

· Omega‑3 fatty acids (EPA/DHA): Improve steatosis in NAFLD; modest AST/ALT reduction in some trials.

· Preferred source: Algae oil – sustainably fermented, re‑esterified triglyceride form, highest bioavailability. No marine contaminants, overfishing, or antibiotic residues.

· Avoid: Conventional fish oil – ecological strain, ocean pollutants.

· Dose: 2–4 g combined EPA+DHA daily.

· Berberine: Plant alkaloid with insulin‑sensitising, lipid‑lowering, and anti‑inflammatory properties. Small trials in NAFLD show improved AST/ALT, steatosis, and insulin resistance.

· Dose: 500 mg twice daily.

· May cause constipation; often combined with liver support (milk thistle) and B vitamins.

· Critical: If B vitamins are included, insist on methylfolate and methylcobalamin – never synthetic folic acid or cyanocobalamin.

· Caution: May interact with CYP450 substrates; contraindicated in pregnancy.

For muscle injury (elevated AST with elevated CK):

· Coenzyme Q10 (Ubiquinol): Statins deplete CoQ10; supplementation (200–400 mg/day) may reduce myalgia in some patients. Limited evidence for AST reduction.

· Preferred form: Ubiquinol (reduced, better absorbed).

· Source: Fermentation‑derived; ecological.

Herbs and Phytochemicals from Indian subcontinent:

· Kutki (Picrorhiza kurroa): Traditional Ayurvedic herb for liver disorders; hepatoprotective in animal models. Limited human trials; small studies suggest reduced transaminases in viral hepatitis.

· Form: Standardised to kutkin or picroside I/II (50–100 mg/day).

· Caution: Bitter, may cause gastrointestinal upset; not for prolonged use without supervision.

· Avoid in pregnancy, autoimmune disease.

· Bhumyamalaki (Phyllanthus niruri): Used in Ayurveda and traditional medicine for jaundice. Meta‑analysis of randomised trials in chronic hepatitis B showed improved ALT normalisation and HBeAg clearance compared to placebo, but quality was low. Not comparable to modern antivirals.

· Form: Standardised extract; dose variable (typically 500–1000 mg twice daily).

· Caution: May cause loose stools.

· Guduchi (Tinospora cordifolia): Immunomodulatory, hepatoprotective; used in Ayurveda for fever, jaundice, and liver disorders. Limited evidence; case series in viral hepatitis.

· Form: Standardised aqueous extract; dose 300–500 mg twice daily.

· Amla (Emblica officinalis): Richest natural vitamin C source; potent antioxidant; hepatoprotective in animal models. May reduce oxidative stress in chronic liver disease.

· Form: Fresh fruit, powder (1 tsp daily), or standardised extract.

· Note: Enhances iron absorption – useful if iron deficiency coexists.

· Punarnava (Boerhavia diffusa): Diuretic, anti‑inflammatory; traditionally used for kidney and liver disorders; limited evidence.

· Tulsi (Ocimum sanctum): Adaptogenic, hepatoprotective; may reduce oxidative stress and lower liver enzymes in animal studies; human data lacking.

· Form: Leaf extract, tea.

· Kalmegh (Andrographis paniculata): Anti‑inflammatory, hepatoprotective; used in Siddha and Ayurveda. Small trials in viral hepatitis show improved enzymes; high‑quality evidence lacking.

· Caution: Bitter; may cause gastrointestinal upset; avoid in pregnancy, autoimmune disease.

Important cautions – supplements and AST:

· Niacin (nicotinic acid) can cause hepatotoxicity and AST elevation, especially sustained‑release formulations. Avoid in liver disease.

· Green tea extract (EGCG) in high doses (>800 mg/day) is associated with hepatotoxicity; case reports of acute liver failure. Do not exceed recommended doses.

· Kava, comfrey, chaparral, germander, pennyroyal oil, certain Chinese herbs – well‑documented hepatotoxins; avoid completely.

· Avoid all proprietary blends containing synthetic folic acid, cyanocobalamin, or undeclared herbal adulterants.

· Stop all non‑essential herbs/supplements at least 7 days before liver biopsy or major surgery.

· Do not use herbal supplements in acute severe hepatitis, acute liver failure, or severe cholestasis without hepatologist guidance.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

No diet directly lowers AST. Dietary strategies target the underlying condition and support liver health.

For NAFLD / metabolic dysfunction:

· Core dietary pattern:

· Mediterranean diet – highest level of evidence for NAFLD. Improves steatosis, inflammation, and insulin resistance.

· High intake of vegetables, fruits, legumes, whole grains, nuts, seeds, extra virgin olive oil.

· Moderate intake of fish (though deprioritised ecologically; plant‑based alternatives preferred).

· Low intake of refined carbohydrates, added sugars, ultra‑processed foods, red meat.

· Weight loss: 5–10% reduction in body weight significantly reduces AST/ALT and steatosis; ≥10% improves fibrosis.

· Avoid fructose: High‑fructose corn syrup and sucrose (50% fructose) are lipogenic and drive de novo lipogenesis. Eliminate sugary beverages completely.

· Coffee: 2–3 cups/day consistently associated with:

· Lower AST/ALT

· Reduced risk of cirrhosis (by up to 50%)

· Slower fibrosis progression in NAFLD, hepatitis C, and HIV/HCV coinfection

· Reduced incidence of hepatocellular carcinoma

· Mechanism: Antioxidants (chlorogenic acids), inhibition of TGF‑β, reduced fibrogenesis

· Extra virgin olive oil: Polyphenols (oleocanthal) have anti‑inflammatory effects; replace butter, margarine, coconut oil.

· Nuts: Walnuts, almonds – rich in unsaturated fats, vitamin E, polyphenols.

· Legumes: Lentils, chickpeas, beans – high fibre, plant protein; replace red meat.

· Turmeric + black pepper: Daily culinary use.

For alcoholic liver disease:

· Absolute abstinence – essential.

· Nutritional repletion: Alcoholics are often malnourished; thiamine (B1), folate, B12, vitamin D, zinc.

· High‑protein diet (1.2–1.5 g/kg/day) unless encephalopathic.

For viral hepatitis (supportive):

· Adequate calorie and protein intake.

· Avoid iron supplementation unless deficiency documented (iron overload harmful in chronic hepatitis C).

· Coffee – as above.

· Avoid raw shellfish – risk of Vibrio vulnificus in cirrhotic patients.

For haemochromatosis:

· Avoid iron supplements.

· Limit vitamin C supplements (>500 mg/day) – may increase iron absorption and mobilisation.

· Avoid raw shellfish – risk of Vibrio vulnificus.

· Tea with meals – tannins inhibit iron absorption.

For Wilson disease:

· Avoid high‑copper foods during initial treatment: liver, shellfish, nuts, chocolate, mushrooms, dried fruits. Less restrictive once stable on chelation therapy.

Fungi:

· Reishi (Ganoderma lucidum): Hepatoprotective in animal studies; limited human evidence. May cause hepatotoxicity in rare cases. Not recommended in active liver disease without specialist guidance.

· Shiitake, maitake, oyster mushrooms: Contain beta‑glucans; general immune support. Safe in moderation.

Algae:

· Spirulina, chlorella: Nutrient‑dense; some evidence of hepatoprotection. Caution in autoimmune liver disease (may stimulate immune system). Reports of hepatotoxicity with contaminated products; use reputable sources.

Dairy and eggs:

· Permitted but not emphasised.

· Fermented dairy (yoghurt, kefir) preferable – probiotics may benefit gut‑liver axis.

· Eggs: Yolks contain cholesterol and choline; choline deficiency causes NAFLD; moderate consumption acceptable.

Foods to absolutely avoid:

· Alcohol – direct hepatotoxin; contraindicated in any liver disease with AST elevation.

· Trans fats (partially hydrogenated oils) – pro‑inflammatory, promote steatosis.

· Red and processed meat – associated with cirrhosis, hepatocellular carcinoma; entirely avoidable.

· Excess refined sugar and high‑fructose corn syrup – drivers of hepatic steatosis.

· Ultra‑processed foods – industrial seed oils, emulsifiers, preservatives.

· Raw or undercooked shellfish – risk of Vibrio vulnificus in cirrhotic patients (mortality >50%).

---

6. How soon can one expect improvement and the ideal time frame to retest

Resolution depends entirely on the underlying cause.

· Acute viral hepatitis:

· AST peaks at 2–4 weeks; declines over 4–8 weeks.

· Normalisation by 2–3 months.

· Retest weekly initially, then monthly.

· Ischaemic hepatitis (shock liver):

· AST falls >50% within 24–72 hours of haemodynamic stabilisation.

· Normalisation by 5–10 days.

· Retest daily during ICU stay, then at 1 week.

· Acetaminophen toxicity (treated with NAC):

· AST peaks at 72–96 hours; begins falling after NAC.

· Normalisation over 1–2 weeks.

· Retest daily until downward trend, then weekly.

· Bile duct obstruction (relieved):

· AST falls within 24–48 hours of ERCP or biliary drainage.

· Normalisation by 1–2 weeks.

· Retest at 1 week; if persistent elevation, evaluate for secondary biliary cirrhosis.

· Alcoholic hepatitis (severe, treated):

· AST declines over 2–4 weeks with corticosteroids and abstinence.

· Lille score at day 7 predicts response.

· Retest at 1 week, then at 4 weeks.

· Autoimmune hepatitis (treated):

· AST improvement evident within 2–4 weeks of starting corticosteroids.

· Normalisation target: 6–12 months.

· Retest at 1, 3, 6 months.

· NAFLD (lifestyle intervention):

· AST reduction measurable at 3–6 months with ≥5% weight loss.

· Maximal improvement at 6–12 months.

· Retest at 3, 6, and 12 months.

· Drug‑induced liver injury (mild):

· AST normalises 2–4 weeks after drug cessation.

· Retest at 2–4 weeks.

· Muscle injury (exercise):

· AST normalises within 24–72 hours of rest.

· Retest in 1 week if persistent.

· Coeliac disease (gluten‑free diet):

· AST normalises within 6–12 months.

· Retest at 6 months.

· Hypothyroidism (levothyroxine):

· AST normalises over 2–6 months with euthyroid state.

· Retest thyroid function and AST at 3 months.

General retesting principles:

· Use the same laboratory for serial comparisons.

· Exclude haemolysis as cause of elevation before acting on result.

· Do not retest more frequently than 48 hours for acute conditions; meaningful change requires time.

· Persistent or progressive elevation despite adequate therapy requires hepatology referral and further investigation (imaging, liver biopsy).

---

Conclusion

Aspartate aminotransferase is the sentinel of cellular injury – a sensitive but promiscuous marker that cannot distinguish liver from heart, muscle, or blood. Its elevation is a call to investigative action, not a target for empirical suppression.

The diagnostic approach is guided by the AST:ALT ratio, the degree of elevation, and the clinical context. A ratio ≥2:1 points toward alcohol; a ratio <1 suggests NAFLD or viral hepatitis. Extreme elevations (>1000 U/L) narrow the field to ischaemia, toxin, acute viral hepatitis, autoimmune hepatitis, or Wilson disease. Mild, isolated elevations are most commonly due to NAFLD, medication effect, or extrahepatic sources.

Treatment is cause‑specific: abstinence in alcoholic liver disease, antivirals in hepatitis B and C, corticosteroids in autoimmune hepatitis, weight loss in NAFLD, N‑acetylcysteine in acetaminophen toxicity, and ERCP in biliary obstruction. There is no "AST‑lowering diet" or "AST‑normalising herb." Adjunctive measures – silymarin, curcumin, berberine, coffee, and a plant‑forward Mediterranean diet – support liver health but do not replace definitive therapy.

As with all blood tests, context is sovereign. Never interpret AST in isolation.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

Special note on NAFLD and NASH:

A whole‑food, plant‑based Mediterranean diet is the most evidence‑based dietary intervention. Coffee (2–3 cups daily) is strongly supported. Red and processed meat should be entirely avoided. Algae‑sourced omega‑3 (EPA/DHA) is the ecologically responsible alternative to fish oil.

-x-x